Myeloma Guidelines Call for Yearly Measurable Residual Disease Testing - Cure Today
Myeloma Guidelines Call for Yearly Measurable Residual Disease Testing Cure Today
Multiple Myeloma News
Identification of broadly tumour-reactive γδ TCRs from multiple myeloma - Nature
Identification of broadly tumour-reactive γδ TCRs from multiple myeloma Nature
OPTIMUM Trial Reports 5-Year Outcomes With Extended Therapy in High-Risk Multiple Myeloma - The ASCO Post
OPTIMUM Trial Reports 5-Year Outcomes With Extended Therapy in High-Risk Multiple Myeloma The ASCO Post
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences - GSK
GSK to acquire potential best-in-class T cell-engager (TCE) for multiple myeloma from Chimagen Biosciences GSK
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma - CancerNetwork
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma CancerNetwork
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma - OncLive
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma OncLive
Striving for a cure for multiple myeloma: What HCPs need to know - jnj.com
Striving for a cure for multiple myeloma: What HCPs need to know jnj.com
Community rallies for Albion man battling incurable blood cancer - Orleans Hub
Community rallies for Albion man battling incurable blood cancer Orleans Hub
GSK doubles down on Chimagen with $750M multiple myeloma wager - Fierce Biotech
GSK doubles down on Chimagen with $750M multiple myeloma wager Fierce Biotech
Cibola coach David Howes is ready for a fight following cancer diagnosis - Albuquerque Journal
Cibola coach David Howes is ready for a fight following cancer diagnosis Albuquerque Journal
Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma - targetedonc.com
Data Increasingly Favor BCMA-Directed Therapy For Early-Relapse Myeloma targetedonc.com
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting - Yahoo Finance
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting Yahoo Finance
Psychosocial Support for Treatment-Related Challenges in Relapsed/Refractory Multiple Myeloma - CancerNetwork
Psychosocial Support for Treatment-Related Challenges in Relapsed/Refractory Multiple Myeloma CancerNetwork
MRD and Treatment Response in Multiple Myeloma - OncLive
MRD and Treatment Response in Multiple Myeloma OncLive
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial - Fierce Biotech
AbbVie bispecific shows promise in ph. 3 multiple myeloma trial Fierce Biotech
Maintaining Quality of Life During Relapsed/Refractory Multiple Myeloma Treatment - CancerNetwork
Maintaining Quality of Life During Relapsed/Refractory Multiple Myeloma Treatment CancerNetwork
Patient Education in Frontline Multiple Myeloma - OncLive
Patient Education in Frontline Multiple Myeloma OncLive
Closing Reflections on BCMA-Directed Therapy in Relapsed/Refractory Multiple Myeloma - CancerNetwork
Closing Reflections on BCMA-Directed Therapy in Relapsed/Refractory Multiple Myeloma CancerNetwork
Iberdomide in Lenalidomide-Refractory Multiple Myeloma - CancerNetwork
Iberdomide in Lenalidomide-Refractory Multiple Myeloma CancerNetwork
Emerging CELMoDs in Multiple Myeloma - CancerNetwork
Emerging CELMoDs in Multiple Myeloma CancerNetwork
Second CAR T-Cell Infusion Hits Myeloma After CELMoD Bridging - Bioengineer.org
Second CAR T-Cell Infusion Hits Myeloma After CELMoD Bridging Bioengineer.org
Mayo Clinic Minute: New approaches bring progress in treating multiple myeloma (VIDEO) - Mayo Clinic News Network
Mayo Clinic Minute: New approaches bring progress in treating multiple myeloma (VIDEO) Mayo Clinic News Network
Quadruplet Therapy and Treatment Individualization in Newly Diagnosed Multiple Myeloma - OncLive
Quadruplet Therapy and Treatment Individualization in Newly Diagnosed Multiple Myeloma OncLive
Relapsed/Refractory Multiple Myeloma: Shared Decision-Making and Treatment Goals - OncLive
Relapsed/Refractory Multiple Myeloma: Shared Decision-Making and Treatment Goals OncLive
A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states - Nature
A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states Nature
New therapeutic target expands options for multiple myeloma - Penn Medicine
New therapeutic target expands options for multiple myeloma Penn Medicine
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M - BioSpace
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M BioSpace
Mayo Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy - Mayo Clinic News Network
Mayo Clinic-led study finds no improvement in overall survival from longer multiple myeloma maintenance therapy Mayo Clinic News Network
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial - Nature
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial Nature
Purpureocillium lilacinum Fungemia Masquerading as an Unidentified Yeast in a Heavily Immunosuppressed Patient With Relapsed Multiple Myeloma and Therapy-Related Mixed-Phenotype Acute Leukemia: A Case Report - Cureus
Purpureocillium lilacinum Fungemia Masquerading as an Unidentified Yeast in a Heavily Immunosuppressed Patient With Relapsed Multiple Myeloma and Therapy-Related Mixed-Phenotype Acute Leukemia: A Case Report Cureus
Teclistamab Improves Outcomes in Relapsed Multiple Myeloma - University of Miami
Teclistamab Improves Outcomes in Relapsed Multiple Myeloma University of Miami
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial - Nature
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial Nature
Redefining light-chain smoldering multiple myeloma: prevalence and progression risk - Nature
Redefining light-chain smoldering multiple myeloma: prevalence and progression risk Nature
Sequencing Therapy After BCMA-Directed CAR T and Bispecific Antibodies in Multiple Myeloma - OncLive
Sequencing Therapy After BCMA-Directed CAR T and Bispecific Antibodies in Multiple Myeloma OncLive
How Will Iberdomide’s Approval and Other CELMoDs Impact Multiple Myeloma? - CancerNetwork
How Will Iberdomide’s Approval and Other CELMoDs Impact Multiple Myeloma? CancerNetwork
Multiple Myeloma: Diagnosis and Treatment - American Academy Of Family Physicians | AAFP
Multiple Myeloma: Diagnosis and Treatment American Academy Of Family Physicians | AAFP
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy - ascopubs.org
High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy ascopubs.org
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse - Bristol Myers Squibb
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse Bristol Myers Squibb
Caroline Pothet։ From CHMP Opinions to the Future of Cell and Gene Therapies - Oncodaily
Caroline Pothet։ From CHMP Opinions to the Future of Cell and Gene Therapies Oncodaily
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma - The ASCO Post
FDA Approves CELMoD Combination Regimen for Pretreated Multiple Myeloma The ASCO Post